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Tetrahydrofuran was distilled over LiAlH4 prior to use. Acetonitrile (ACN), dichloromethane (DCM), N,N-
dimethylformamide (DMF), methanol (MeOH), diisopropylethylamine (DiPEA) and trifluoroacetic acid (TFA) 
were of peptide synthesis grade, purchased at Biosolve, and used as received. All general chemicals (Fluka, 
Acros, Merck, Aldrich, Sigma) were used as received. O-(1H-6-Chlorobenzotriazolyl)-1,1,3,3-
tetramethyluronium hexafluorophosphate (HCTU) was purchased at Iris Biotech (Marktrewitz, Germany). 
Traces of water were removed from reagents used in reactions that require anhydrous conditions by co-
evaporation with toluene. Solvents that were used in reactions were stored over 4 Å molecular sieves, except 
methanol and acetonitrile which were stored over 3 Å molecular sieves. Molecular sieves were flame dried 
before use. Unless noted otherwise all reactions were performed under an argon atmosphere. Column 
chromatography was performed on Screening Devices b.v. Silica Gel, with a particle size of 40-63 m and pore 
diameter of 60 Å. The eluents toluene, ethyl acetate (EtOAc) and petroleum ether (PE) (40-60 °C boiling range) 
were distilled prior to use. TLC analysis was conducted on Merck aluminium sheets (Silica gel 60 F254). 
Compounds were visualized by UV absorption (254 nm), by spraying with a solution of (NH4)6Mo7O24·4H2O 
(25 g/L) and (NH4)4Ce(SO4)4·2H2O (10 g/L) in 10% sulfuric acid, a solution of KMnO4 (20 g/L) and K2CO3 (10 
g/L) in water, or ninhydrin (0.75 g/L) and acetic acid (12.5 mL/L) in ethanol, where appropriate, followed by 
charring at ca. 150 C. 1H- and 13C-NMR spectra were recorded on a Bruker AV-400 (400 MHz) spectrometer. 
Chemical shifts are given in ppm () relative to tetramethylsilane, CD3OD or CDCl3 as internal standard. High 
resolution mass spectra were recorded by direct injection (2 µL of a 2 µM solution in water/acetonitrile 50/50 
(v/v) and 0.1% formic acid) on a mass spectrometer (Thermo Finnigan LTQ Orbitrap) equipped with an 
electrospray ion source in positive mode (source voltage 3.5 kV, sheath gas flow 10, capillary temperature 250 
C) with resolution R = 60,000 at m/z 400 (mass range m/z = 150-2000) and dioctylpthalate (m/z = 391.28428) as 
a “lock mass”. The high resolution mass spectrometer was calibrated prior to measurements with a calibration 
mixture (Thermo Finnigan). Optical rotations  were recorded on a Propol automatic polarimeter. LC-MS 
analysis was performed on a Jasco HPLC system with a Phenomenex Gemini 3 lm C18 50 × 4.60 mm column 
(detection simultaneously at 214 and 254 nm), coupled to a PE Sciex API 165 mass spectrometer with ESI 
(System A) or a Finnigan Surveyor HPLC system with a Gemini C18 50  4.60 mm column (detection at 200-
600 nm), coupled to a Finnigan LCQ Advantage Max mass spectrometer with ESI (System B). The applied 
buffers were H2O, ACN and 1.0% aq. TFA. Unless noted otherwise the gradient used was 10% → 90% 
ACN/0.1% aq. TFA. HPLC purifications were performed on a Gilson HPLC system coupled to a Phenomenex 
Gemini 5 μm 250  10 mm column and a GX281 fraction collector. The applied buffers were: 0.1% aq. TFA and 
ACN. Appropriate fractions were pooled, and concentrated in a Christ rotary vacuum concentrator overnight at 





2,6-diisopropylphenol (2, 18.4 g, 100 mmol) was dissolved in AcOH (83 mL) and H2O (17 mL). To this was 
added hexamine (2 eq., 200 mmol, 28.0 g) and the mixture was heated to reflux for 5 min. after which a 
distillation head was installed and ca. 9 mL distillate was collected at 110 ºC. The distillation head was removed 
again and the mixture was refluxed for another 2.5 h after which TLC analysis indicated complete consumption 
of the phenol starting compound. Next, the mixture was cooled to RT and H2O (20 mL) was added. Upon further 
cooling to 0 ºC a pale yellow solid precipitated. The mixture was allowed to stand at 0 ºC for 1 h followed by 
filtration of the solid. The residue was washed two times with ice-cold water and dried at 60 ºC under reduced 
pressure. The title compound was obtained without further purification as a pale yellow solid (yield: 20.1 g, 97.6 
mmol, 97%). 1H NMR (400 MHz, CDCl3 ppm 9.79 (s, 1H), 7.62 (s, 2H), 4.14 (bs, 1H), 3.30 (p, J = 6.80 Hz, 




Phenol 3 (4.14 g, 20.0 mmol) was dissolved in acetone (100 mL) and to this were added benzylbromide (1.01 
eq., 20.2 mmol, 3.46 g) and K2CO3 (2 eq., 40.0 mmol, 5.53 g). The suspension was stirred vigorously for 14 h 
after which TLC analysis revealed a completed reaction. The mixture was concentrated under reduced pressure, 
redissolved in EtOAc (100 mL) and extracted with H2O and brine. After drying (MgSO4) and concentration in 
vacuo of the organic layer the title compound was obtained as a colorless oil (yield: 5.50 g, 18.6 mmol, 93%). 1H 
NMR (400 MHz, CDCl3 ppm 9.95 (s, 1H), 7.70 (s, 2H), 7.48 (d, J = 7.18 Hz, 2H), 7.41 (t, J = 7.30 Hz, 2H), 
7.35 (t, J = 7.20 Hz, 1H), 4.86 (s, 2H), 3.41 (sept., J = 6.85 Hz, 2H), 1.27 (d, J = 6.96 Hz, 12H). 13C NMR (100 
MHz, CDCl3)  ppm 191.68, 158.53, 143.13, 136.76, 133.13, 128.50, 128.07, 127.25, 126.13, 76.42, 26.66, 
23.74. 
 
(E)-tert-butyl 3-(4-(benzyloxy)-3,5-diisopropylphenyl)acrylate (6) 
To a stirred solution of aldehyde 4 (0.23 g, 0.76 mmol) and tert-butyl 2-(diethoxyphosphoryl)acetate (5, 1.5 eq., 
1.14 mmol, 0.29 g) in THF (10 mL) at 0 ºC was added NaH (1.5 eq., 1.14 mmol, 46.0 mg). The reaction mixture 
was stirred for 1 h at RT after which TLC analysis indicated a completed reaction. EtOAc (10 mL) was added 
and the mixture was extracted with 0.1 M aq. HCl (2×), sat. aq. NaHCO3 and brine. The organic layer was dried 
over MgSO4 and concentrated under reduced pressure. The title compound was obtained after purification by 
column chromatography (100% PE → 5% EtOAc/PE) as a colorless oil (yield: 0.31 g, 0.77 mmol, quant.). 1H 
NMR (400 MHz, CDCl3 ppm 7.60 (d, J = 15.94 Hz, 1H), 7.47 (d, J = 7.08 Hz, 2H), 7.40 (t, J = 7.31 Hz, 
2H), 7.33 (t, J = 7.24 Hz, 1H), 7.30 (s, 2H), 6.33 (d, J = 15.93 Hz, 1H), 4.81 (s, 2H), 3.38 (sept., J = 6.89 Hz, 
2H), 1.54 (s, 9H), 1.24 (d, J = 6.91 Hz, 12H). 13C NMR (100 MHz, CDCl3)  ppm 166.38, 154.87, 143.78, 
142.42, 137.20, 130.97, 128.47, 127.94, 127.26, 124.02, 118.73, 80.14, 76.36, 28.13, 26.54, 23.88. HRMS: 




Tert-butyl 3-(4-hydroxy-3,5-diisopropylphenyl)propanoate (7) 
Compound 6 (0.30 g, 0.76 mmol) was dissolved in MeOH (10 mL) and the solution was bubbled through with 
argon for 15 min. before Pd/C 10% w/w (10 mg) was added. The flask was charged with hydrogen for 1 h, after 
which TLC analysis indicated complete reduction. Argon was bubbled through for another 15 min. and all solids 
were removed by filtration over Celite. The title compound was obtained after evaporation of the solvent under 
reduced pressure as a colorless oil (yield: 0.22 g, 0.71 mmol, 94%). 1H NMR (400 MHz, CDCl3 ppm 6.87 (s, 
2H), 5.09 (s, 1H), 3.17 (sept., J = 6.80 Hz, 2H), 2.85 (t, J = 7.84 Hz, 2H), 2.52 (t, J = 7.86 Hz, 2H), 1.42 (s, 9H), 
1.24 (d, J = 6.91 Hz, 12H). 13C NMR (100 MHz, CDCl3)  ppm 172.73, 148.26, 133.75, 132.36, 123.10, 80.17, 
37.51, 30.83, 27.98, 27.00, 22.73. HRMS: calcd. for C19H30O3 329.20872 [M+ Na]+; found 329.20871. 
 
Diethyl 3,3'-(1,3-dioxolane-2,2-diyl)dipropanoate (9)[2] 
Diethyl-4-oxopimelate (8, 11.4 g, 48.4 mmol), ethylene glycol (436 mmol, 24.0 mL) and PPTS (7.26 mmol, 1.82 
g) were dissolved in toluene (50 mL) and the mixture was heated to reflux under Dean-Stark conditions for 2 h, 
after which TLC analysis indicated complete consumption of the ketone. The mixture was cooled to RT and 
extracted twice with sat. aq. NaHCO3 (50 mL). The organic layer was dried over MgSO4 and concentrated under 
reduced pressure. The title compound was obtained as a colorless liquid (yield: 13.2 g, 48.4 mmol, quant.). 1H 
NMR (300 MHz, CDCl3 ppm 4.13 (q, J = 7.13 Hz, 4H), 3.94 (s, 4H), 2.37 (t, J = 7.65 Hz, 4H), 1.98 (t, J = 
7.64 Hz, 4H), 1.25 (t, J = 7.14 Hz, 6H). 13C NMR (75.5 MHz, CDCl3) ppm 173.24, 109.84, 65.02, 60.20, 
32.07, 28.78, 14.07. 
 
Ethyl 3-(2-(3-hydroxypropyl)-1,3-dioxolan-2-yl)propanoate (10) 
A solution of KOH (47.7 mmol, 47.7 mL; 1 M in EtOH) was added dropwise to diethyl ester 9 (13.2 g, 47.7 
mmol) at 50 ºC in 4 h. The resulting mixture was stirred at 50 ºC for 14 h after which all EtOH was evaporated 
under reduced pressure. The resulting residue was suspended in THF (250 mL) and Et3N (0.5 eq., 23.8 mmol, 
3.31 mL) and ethyl chloroformate (1.5 eq., 71.5 mmol, 6.84 mL) were added. After vigorously stirring for 2 h 
the mixture was added to a cooled (0 ºC) solution of NaBH4 (1.5 eq., 71.5 mmol, 2.71 g) in H2O (250 mL) and 
the mixture was stirred at RT for 1 h. The reaction was quenched by addition of 1 mM aq. HCl (100 mL) and the 
resulting mixture was extracted with Et2O (3×). The combined organic layers were extracted with brine, dried 
over MgSO4 and concentrated under reduced pressure. The title compound was obtained after purification by 
column chromatography (25% → 100% EtOAc/PE) as a colorless liquid (yield: 4.14 g, 17.8 mmol, 37%). 1H 
NMR (300 MHz, CDCl3 ppm 4.13 (q, J = 7.13 Hz, 2H), 3.96 (s, 4H), 3.64 (t, J = 5.83 Hz, 2H), 2.37 (t, J = 
7.75 Hz, 2H), 2.01 (t, J = 7.65 Hz, 2H), 1.93 (bs, 1H), 1.76-1.62 (m, 4H), 1.26 (t, J = 7.13 Hz, 3H). 13C NMR 
(75.5 MHz, CDCl3) ppm 208.84, 110.72, 65.00, 62.84, 60.34, 33.79, 31.90, 28.92, 26.89, 14.15. HRMS: calcd. 
for C11H20O5 255.12029 [M+ Na]+; found 255.12036. 
 
Ethyl 3-(2-(3-(tosyloxy)propyl)-1,3-dioxolan-2-yl)propanoate (11) 
Alcohol 10 (4.14 g, 17.8 mmol) was dissolved in DCM (125 mL) and Et3N (2.1 eq., 37.4 mmol, 5.18 mL), 
DMAP (0.25 eq., 4.45 mmol, 0.50 g) and TsCl (2.55 eq., 8.66 mmol, 45.4 g) were added. The mixture was 
stirred for 4 h after which TLC analysis indicated a complete consumption of the starting compound. DCM was 
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evaporated under reduced pressure and the residue was dissolved in EtOAc, extracted with 1 mM aq. HCl (2×) 
and brine, dried over MgSO4 and concentrated under reduced pressure. The title compound was obtained after 
purification by column chromatography (25% → 50% EtOAc/PE) as a colorless liquid (yield: 5.87 g, 15.2 
mmol, 85%). 1H NMR (400 MHz, CDCl3)  ppm 7.79 (d, J = 8.0 Hz, 2H), 7.34 (d, J = 8.4 Hz, 2H), 4.12 (q, J = 
7.1 Hz, 2H), 4.04 (t, J = 6.4 Hz, 2H), 3.9-3.8 (m, 4H), 2.45 (s, 3H), 2.31 (t, J = 7.6 Hz, 2H), 1.92 (t, J = 7.6 Hz, 
2H), 1.8-1.7 (m, 2H), 1.7-1.6 (m, 2H), 1.26 (t, J = 6.8 Hz, 3H); 13C NMR (100 MHz, CDCl3)  ppm 173.38, 
144.80, 133.30, 129.80, 127.86, 110.15, 70.53, 65.06, 60.36, 33.01, 32.07, 28.83, 23.39, 21.60, 14.19. 
 
Ethyl 3-(2-(3-azidopropyl)-1,3-dioxolan-2-yl)propanoate (12) 
A solution of tosylate 11 (5.87 g, 15.2 mmol) and NaN3 (1.2 eq., 18.2 mmol, 1.19 g) in DMF (120 mL) was 
stirred at 75 ºC for 14 h, after which TLC analysis indicated a complete conversion. The mixture was 
concentrated under reduced pressure and the residue was dissolved in EtOAc, extracted with sat. aq. NaHCO3 
(2×), H2O and brine, dried over MgSO4 and concentrated under reduced pressure. The title compound was 
obtained as a colorless liquid (yield: 3.86 g, 15.0 mmol, 99%). 1H NMR (400 MHz, CDCl3 ppm 4.13 (q, J = 
7.14 Hz, 2H), 3.94 (s, 4H), 3.32-3.26 (m, 2H), 2.36 (t, J = 7.60 Hz, 2H), 1.99 (t, J = 7.60 Hz, 2H), 1.71-1.65 (m, 
4H), 1.26 (t, J = 7.15 Hz, 3H). 13C NMR (100 MHz, CDCl3)  ppm 173.23, 110.20, 64.93, 60.17, 51.29, 34.07, 
31.94, 28.73, 23.24, 14.04. HRMS: calcd. for C11H19N3O4 258.14483 [M+ H]+; found 258.14491. IR film (cm-1) 
2954.7, 2885.3, 2360.7, 2090.7, 1728.1, 1450.4, 1257.5, 1180.3, 1134.1, 1033.8, 948.9, 910.3, 864.1. 
 
3-(2-(3-azidopropyl)-1,3-dioxolan-2-yl)propanoic acid (13) 
Ethyl ester 12 (3.86 g, 15.0 mmol) was dissolved in MeOH (80 mL) and to this was added NaOH (4 eq., 60.0 
mmol, 30 mL; 2 M in H2O) at 0 ºC. The mixture was allowed to slowly warm to RT and was stirred for 14 h 
after which TLC analysis revealed complete conversion. The mixture was concentrated under reduced pressure 
and the residue was dissolved in sat. aq. NaHCO3/H2O (3:1 v/v, 80 mL) and extracted twice with EtOAc. Next, 
the aqueous layer was acidified with 10% w/v aq. HCl until pH 2 and extracted again twice with EtOAc. The 
latter organic layers were combined, dried over MgSO4 and concentrated under reduced pressure, which yielded 
the title compound as a colorless liquid (yield: 3.05 g, 13.3 mmol, 89%). 1H NMR (300 MHz, CDCl3 ppm 
10.20 (bs, 1H), 3.96 (s, 4H), 3.34-3.25 (m, 2H), 2.41 (t, J = 7.50 Hz, 2H), 2.00 (t, J = 7.51 Hz, 2H), 1.71-1.65 
(m, 4H). 13C NMR (100 MHz, CDCl3)  ppm 179.31, 110.16, 64.95, 51.23, 34.07, 31.68, 28.46, 23.21. 
 
7-azido-4-oxoheptanoic acid (14) 
Concentrated aq. HCl (19 mL) was added to a solution of compound 13 (3.05 g, 13.3 mmol) in THF (60 mL) and 
the mixture was stirred for 3 h, after which TLC analysis showed complete consumption of starting material. 
Water (150 mL) was added carefully and the aqueous layer was extracted with EtOAc three times. The 
combined organic layers were extracted with brine, dried over MgSO4 and concentrated in vacuo. The title 
compound was obtained as a colorless oil (yield: 2.46 g, 13.3 mmol, quant.) without further purification 
necessary. 1H NMR (400 MHz, CDCl3 ppm 9.26 (bs, 1H), 3.32 (t, J = 6.64 Hz, 2H), 2.73 (t, J = 6.20 Hz, 
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2H), 2.64 (t, J = 6.16 Hz, 2H), 2.57 (t, J = 7.06 Hz, 2H), 1.88 (p, J = 6.86 Hz, 2H). 13C NMR (100 MHz, CDCl3) 
 ppm 207.65, 178.28, 50.56, 39.10, 36.80, 27.68, 22.79. 
 
4-(3-(tert-butoxy)-3-oxopropyl)-2,6-diisopropylphenyl 7-azido-4-oxoheptanoate (15) 
To a solution of alcohol 7 (1 eq., 13.3 mmol, 4.08 g), carboxylic acid 14 (1 eq., 13.3 mmol, 2.46 g) and DMAP 
(0.1 eq., 1.33 mmol, 0.16 g) in DCM (100 mL) was added DIC (1.2 eq., 16.0 mmol, 2.51 mL) and the mixture 
was stirred for 14 h. Next, the mixture was concentrated under reduced pressure, the residue dissolved in EtOAc 
(100 mL), extracted with 1 M aq. HCl (2×), sat. aq. NaHCO3 and brine, dried (MgSO4) and concentrated under 
reduced pressure. The title compound was obtained after purification by column chromatography (100% Tol → 
10% EtOAc/Tol) as a colorless oil (yield: 4.41 g, 9.64 mmol, 73%). 1H NMR (400 MHz, CDCl3 ppm 6.96 (s, 
2H), 3.30 (t, J = 6.68 Hz, 2H), 2.93-2.80 (m, 8H), 2.58 (t, J = 7.06 Hz, 2H), 2.53 (t, J = 7.83 Hz, 2H), 1.87 (p, J 
= 6.88 Hz, 2H), 1.42 (s, 9H), 1.17 (d, J = 6.91 Hz, 12H). 13C NMR (100 MHz, CDCl3)  ppm 207.21, 172.21, 
171.48, 143.67, 140.03, 138.61, 123.69, 80.15, 50.52, 39.19, 36.95, 36.88, 30.90, 27.95, 27.65, 27.32, 22.85. 
HRMS: calcd. for C26H39N3O5 496.27819 [M+ Na]+; found 496.27775. 
 
3-(4-((7-azido-4-oxoheptanoyl)oxy)-3,5-diisopropylphenyl)propanoic acid (16) 
TFA (10 mL) was added to a solution of tert-butyl ester 15 (1.40 g, 3.06 mmol) in DCM (10 mL) and this 
mixture was stirred for 30 min. after which TLC analysis showed complete consumption of starting material. 
Toluene (25 mL) was added and the mixture was concentrated under reduced pressure. In order to remove traces 
of TFA the mixture was coevaporated with toluene three times. The title compound was obtained as a colorless 
oil (yield: 1.41 g, 3.52 mmol, quant.). 1H NMR (400 MHz, CDCl3 ppm 9.40 (s, 1H), 6.98 (s, 2H), 3.29 (t, J = 
6.69 Hz, 2H), 2.95-2.81 (m, 8H), 2.67 (t, J = 7.91 Hz, 2H), 2.59 (t, J = 7.06 Hz, 2H), 1.87 (p, J = 6.92 Hz, 2H), 
1.17 (d, J = 6.91 Hz, 12H). 13C NMR (100 MHz, CDCl3)  ppm 207.43, 178.29, 171.58, 143.75, 140.18, 138.08, 
123.64, 50.44, 39.14, 36.82, 35.59, 30.48, 27.59, 27.27, 22.79. HRMS: calcd. for C22H31N3O5 440.21559 [M+ 
Na]+; found 440.21539. 
 
4-(3-((2,5-dioxopyrrolidin-1-yl)oxy)-3-oxopropyl)-2,6-diisopropylphenyl 7-azido-4-oxoheptanoate (17) 
N-hydroxysuccinimide (1.5 eq., 1.30 mmol, 150 mg) and EDC (1.5 eq., 1.30 mmol, 249 mg) were added to a 
solution of carboxylic acid 16 (0.36 g, 0.87 mmol) in DCM (7 mL) and the mixture was stirred for 14 h, after 
which TLC analysis indicated complete consumption of starting material. The solvent was evaporated under 
reduced pressure and the residue was dissolved in EtOAc (20 mL). This was extracted with 1 M aq. HCl (2×) 
and brine, dried over MgSO4 and concentrated under reduced pressure. The title compound was obtained after 
purification by column chromatography (30% → 60% EtOAc/PE) as a colorless oil (yield: 0.43 g, 0.83 mmol, 
95%). 1H NMR (400 MHz, CDCl3 ppm 6.99 (s, 2H), 3.31 (t, J = 6.67 Hz, 2H), 3.06-3.00 (m, 2H), 2.95-2.81 
(m, 12H), 2.60 (t, J = 7.06 Hz, 2H), 1.88 (p, J = 6.90 Hz, 2H), 1.18 (d, J = 6.89 Hz, 12H). 13C NMR (100 MHz, 
CDCl3)  ppm 207.26, 171.53, 169.03, 167.90, 144.16, 140.59, 137.15, 123.75, 50.60, 39.28, 36.95, 32.70, 
30.35, 27.70, 27.44, 25.54, 22.91. LC-MS (System A): Rt (min): 9.38 (ESI-MS (m/z): 515.4 (M + H+)). HRMS: 
calcd. for C26H34N4O7 515.25003 [M+ H]+; found 515.24963. 
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Fmoc-Ile-Thr(tBu)-OMe (22) 
Fmoc-Ile-OH (1.2 eq., 13.3 mmol, 4.70 g) was dissolved in DCM (60 mL) and to this were added HCTU (1.2 
eq., 13.3 mmol, 5.50 g), DiPEA (3.3 eq., 36.0 mmol, 6.0 mL) and HCl·H-Thr(tBu)-OH (1 eq., 11.0 mmol, 2.50 
g) successively. The mixture was stirred for 2 h after which TLC analysis indicated a completed reaction. DCM 
was evaporated under reduced pressure and the residue was dissolved in EtOAc, extracted with 1 M aq. HCl 
(2×), sat. aq. NaHCO3 (2×) and brine, dried over MgSO4 and concentrated under reduced pressure. The title 
compound was obtained after purification by column chromatography (10% → 50% EtOAc/PE) as a colorless 
solid (yield: 5.16 g, 9.83 mmol, 89%). 1H NMR (400 MHz, CDCl3 ppm 7.76 (d, J = 7.48 Hz, 2H), 7.60 (d, J 
= 7.41 Hz, 2H), 7.39 (t, J = 7.46 Hz, 2H), 7.31 (dt, J = 7.43, 0.98 Hz, 2H), 6.48 (d, J = 8.84 Hz, 1H), 5.58 (d, J 
= 8.70 Hz, 1H), 4.49 (dd, J = 9.00, 1.68 Hz, 1H), 4.44-4.33 (m, 2H), 4.28-4.21 (m, 2H), 4.18 (dd, J = 8.53, 6.39 
Hz, 1H), 3.71 (s, 3H), 1.94-1.83 (m, 1H), 1.65-1.53 (m, 1H), 1.33-1.21 (m, 1H), 1.17 (d, J = 6.27 Hz, 3H), 1.11 
(s, 9H), 1.02-0.94 (m, 6H). 13C NMR (100 MHz, CDCl3)  ppm 171.42, 170.86, 156.07, 143.78, 141.24, 127.63, 
127.01, 125.07, 119.90, 74.21, 67.19, 66.96, 59.30, 57.83, 52.13, 47.17, 38.18, 28.27, 24.82, 21.04, 15.08, 11.52. 
LC-MS (System B): Rt (min): 10.87 (ESI-MS (m/z): 525.0 (M + H+)). 
 
Boc-Ile-Ile-Thr(tBu)-NHNH2 (23) 
DBU (1.05 eq., 10.3 mmol, 1.57 mL) was added to a solution of Fmoc-Ile-Thr(tBu)-OMe (22, 5.16 g, 9.83 
mmol) in DMF (50 mL) and the mixture was stirred for 5 min. after which HOBt (1.5 eq., 14.7 mmol, 1.98 g) 
was added. After stirring the mixture for another 30 min. Boc-Ile-OH (1.2 eq., 11.8 mmol, 2.73 g), HCTU (1.2 
eq., 11.8 mmol, 4.88 g) and DiPEA (3 eq., 29.5 mmol, 4.87 mL) were added. TLC analysis indicated sufficient 
product formation after 14 h and the mixture was concentrated under reduced pressure. The residue was 
redissolved in DCM and extracted with 1 M aq. HCl (2×), sat. aq. NaHCO3 (2×) and brine, dried over MgSO4 
and concentrated in vacuo. The intermediate was purified by column chromatography (10% → 50% EtOAc/PE) 
and the obtained product (3.69 g, 7.15 mmol) was dissolved in MeOH (50 mL). Hydrazine monohydrate (30 eq., 
215 mmol, 10.4 mL) was added and the mixture was stirred for 14 h, after which TLC analysis indicated 
complete consumption of starting material. Toluene was added and the mixture was concentrated under reduced 
pressure. The title compound was obtained after coevaporation with toluene (3×) as a colorless solid (yield: 3.66 
g, 7.10 mmol, 72%). 1H NMR (400 MHz, CD3OD ppm 4.34 (d, J = 3.53 Hz, 1H), 4.29 (d, J = 8.12 Hz, 1H), 
4.05-3.99 (m, 1H), 3.92 (d, J = 7.90 Hz, 1H), 1.90-1.70 (m, 2H), 1.61-1.47 (m, 2H), 1.42 (s, 3H), 1.22-1.10 (m, 
1H), 1.17 (s, 9H), 1.08 (d, J = 6.32 Hz, 3H), 0.92-0.85 (m, 12H). 13C NMR (100 MHz, CD3OD)  ppm 174.83, 
173.39, 171.30, 157.91, 80.56, 75.84, 68.52, 60.62, 59.22, 58.56, 37.94, 37.85, 28.77, 28.66, 25.94, 19.78, 16.23, 
15.95, 11.39, 11.32. LC-MS (System A): Rt (min): 6.08 (ESI-MS (m/z): 516.4 (M + H+)). HRMS: calcd. for 
C25H49N5O6 516.37556 [M+ H]+; found 516.37530. 
 
Boc-Ile-Ile-Thr(tBu)-Leu-EK (24) 
Boc-Ile-Ile-Thr(tBu)-NHNH2 (23, 1 eq., 3.87 mmol, 2.0 g) was dissolved in a 9:1 v/v mixture of DCM/DMF (40 
mL) and cooled to –30 ºC. To this were added tBuONO (1.1 eq., 4.25 mmol, 0.57 mL) and HCl (2.8 eq., 10.8 
mmol, 2.70 mL; 4 M in 1,4-dioxane). This mixture was stirred at –30 ºC for 3 h, after which (S)-2-amino-4-
methyl-1-((R)-2-methyloxiran-2-yl)pentan-1-one TFA salt[3] (1.1 eq., 4.25 mmol, 1.16 g) in DMF (5 mL) and 
 S7
DiPEA (5 eq., 20.0 mmol, 3.31 mL) were added. The reaction was allowed to warm to RT and stirred for 14 h. 
Next, DCM (15 mL) was added and the mixture was extracted with 0.1 M aq., HCl (2×) and H2O, dried over 
MgSO4 and concentrated under reduced pressure. The title compound was obtained after purification by column 
chromatography (20% → 50% EtOAc/PE) as a colorless solid (yield: 2.25 g, 3.43 mmol, 89%). 1H NMR (400 
MHz, CDCl3 ppm 7.64 (d, J = 7.47 Hz, 1H), 6.99 (d, J = 5.63 Hz, 1H), 6.45 (d, J = 8.22 Hz, 1H), 5.22 (d, J 
= 7.84 Hz, 1H), 4.46 (ddd, J = 10.45, 7.55, 2.94 Hz, 1H), 4.41-4.32 (m, 2H), 4.14-4.07 (m, 1H), 3.94 (t, J = 7.34 
Hz, 1H), 3.38 (d, J = 5.07 Hz, 1H), 2.89 (d, J = 5.06 Hz, 1H), 1.92-1.77 (m, 2H), 1.74-1.63 (m, 1H), 1.60-1.55 
(m, 1H), 1.54-1.48 (m, 2H), 1.52 (s, 3H), 1.44 (s, 9H), 1.33-1.24 (m, 1H), 1.28 (s, 9H), 1.19-1.08 (m, 2H), 1.06 
(d, J = 6.44 Hz, 3H), 0.96 (d, J = 6.54 Hz, 6H), 0.92-0.86 (m, 12H). 13C NMR (100 MHz, CDCl3)  ppm 208.06, 
171.59, 170.73, 169.51, 155.80, 79.76, 75.49, 66.14, 59.24, 57.68, 56.95, 52.39, 50.74, 39.80, 37.30, 36.97, 
28.28, 28.08, 25.42, 24.88, 24.69, 23.35, 21.35, 16.75, 16.33, 15.53, 15.40, 11.28. LC-MS (System B): Rt (min): 
11.33 (ESI-MS (m/z): 655.27 (M + H+)). HRMS: calcd. for C34H62N4O8 655.46404 [M+ H]+; found 655.46451. 
 
N3-Lev-phenol-epoxomicin (19) 
Compound 24 (165 mg, 0.25 mmol) was treated with a 1:1 v/v mixture of DCM/TFA (2 mL) for 1 h and 
subsequently coevaporated with toluene (3×). The resulting intermediate was dissolved in DMF (2 mL) and to 
this were added compound 17 (1.1 eq., 0.258 mmol, 144 mg) and DiPEA (2 eq., 0.50 mmol, 83 µL). The 
reaction was stirred for 14 h before being concentrated under reduced pressure. The residue was dissolved in 
DCM (10 mL) and extracted with 1 M aq. HCl (2×), sat. aq. NaHCO3 (2×) and brine, dried over MgSO4 and 
concentrated under reduced pressure. The title compound was obtained after purification by column 
chromatography (25% → 100% EtOAc/PE) as a colorless solid (yield: 141 mg, 0.16 mmol, 63%). 1H NMR (400 
MHz, CDCl3 ppm 8.75 (s, 1H), 8.28 (s, 1H), 8.24 (s, 1H), 7.46 (s, 1H), 6.97 (s, 2H), 4.94-4.76 (m, 3H), 4.63-
4.55 (m, 1H), 4.34 (s, 1H), 4.09-4.01 (m, 1H), 3.31 (t, J = 6.64 Hz, 2H), 3.22 (s, 1H), 3.00-2.77 (m, 9H), 2.59 (t, 
J = 7.01 Hz, 4H), 1.88 ( p, J = 6.89 Hz, 2H), 1.83-1.73 (m, 1H), 1.70-1.35 (m, 8H), 1.49 (s, 3H), 1.20-1.06 (m, 
15H), 0.91-0.71 (m, 18H). 13C NMR (100 MHz, CDCl3) ppm 208.14, 207.22, 172.12, 171.40, 170.57, 143.75, 
140.05, 138.75, 123.71, 67.38, 58.99, 57.47, 57.44, 57.16, 52.12, 50.53, 50.41, 39.22, 38.07, 37.77, 36.92, 31.56, 
27.65, 27.37, 25.29, 25.14, 24.88, 23.12, 22.85, 21.09, 17.35, 16.65, 15.20, 15.16, 11.51, 11.35. = –0.57 (c 
= 1, CHCl3). LC-MS (System B): Rt (min): 10.66 (ESI-MS (m/z): 898.40 (M + H+)). HRMS: calcd. for 




Boc-Ahx-propargylamide[4] (275 mg, 1.03 mmol) was treated with a 1:1 v/v mixture of DCM/TFA (6 mL) for 1 
h and subsequently coevaporated with toluene (3×). The resulting intermediate was dissolved in DMF (5 mL) 
and to this were added biotin-OSu (1.1 eq., 1.1 mmol, 375 mg) and DiPEA (1.5 eq., 1.50 mmol, 248 µL). The 
reaction was stirred for 14 h before being concentrated under reduced pressure. The title compound was obtained 
after crystallisation from MeOH/Et2O as a colorless solid. The compound was sufficiently pure based on LC-MS 
analysis and subjected to the next step without further purification. LC-MS (System B): Rt (min): 4.27 (ESI-MS 




To a solution of compound 19 (45.0 mg, 50.1 µmol) and biotin-Ahx-propargylamide (20, 1.5 eq., 70.0 µmol, 
30.0 mg) in DMF (1.5 mL) were added CuSO4 (0.2 eq., 10.0 µmol, 10.0 µL; 1 M in H2O) and sodium ascorbate 
(0.3 eq., 15.0 µmol, 15.0 µL; 1 M in H2O) and the mixture was stirred for 14 h at RT after which LC-MS 
analysis indicated a complete conversion of the azide. The mixture was concentrated under reduced pressure and 
the title compound was obtained after RP-HPLC purification (10% → 90% ACN/0.1% aq. TFA) as a colorless 
solid (yield: 26.3 mg, 20.4 µmol, 41%). 1H NMR (400 MHz, CD3OD ppm 7.76 (s, 1H), 6.92 (s, 2H), 4.45 
(dd, J = 10.68, 3.02 Hz, 1H), 4.38 (dd, J = 7.43, 5.04 Hz, 1H), 4.34-4.26 (m, 4H), 4.22 (d, J = 5.04 Hz, 1H), 
4.19 (dd, J = 7.87, 4.49 Hz, 1H), 4.15 (d, J = 7.99 Hz, 1H), 4.10 (d, J = 8.14 Hz, 1H), 3.93 (dd, J = 6.19, 5.28 
Hz, 1H), 3.15 (d, J = 5.07 Hz, 1H), 3.12-3.08 (m, 1H), 3.05 (t, J = 7.07 Hz, 2H), 2.87-2.70 (m, 10H), 2.59 (d, J 
= 12.70 Hz, 1H), 2.51-2.39 (m, 4H), 2.15-2.01 (m, 6H), 1.81-1.70 (m, 1H), 1.69-1.37 (m, 12H), 1.36 (s, 3H), 
1.35-1.17 (m, 6H), 1.10-1.01 (m, 16H), 1.00-0.88 (m, 1H), 0.86-0.77 (m, 12H), 0.76-0.69 (m, 6H). 13C NMR 
(100 MHz, CD3OD) ppm 209.52, 209.43, 176.00, 175.27, 174.10, 173.71, 173.61, 172.25, 145.32, 141.72, 
140.24, 124.93, 68.57, 63.45, 61.69, 60.14, 59.84, 59.41, 59.32, 57.06, 53.10, 51.85, 50.58, 41.09, 40.37, 40.23, 
39.53, 38.73, 38.04, 37.88, 37.79, 36.85, 35.64, 32.80, 30.16, 29.83, 29.54, 28.68, 28.61, 27.58, 26.98, 26.54, 
26.26, 26.05, 25.46, 23.82, 21.53, 20.06, 17.06, 16.01, 15.97, 11.49, 11.37. = –1.28 (c = 1, MeOH). LC-
MS (System B): Rt (min): 8.42 (ESI-MS (m/z): 1292.53 (M + H+)). HRMS: calcd. for C66H105N11O13S 




Structure of Ada-(Ahx)3-Leu2-LeuVS (AdaKBio, 21)[5] 
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Stability check and optimization of the cleavage 
 
Table S1: Stability/cleavage of the indicated test-substrate (10 mM) under different conditions.[a] 
Entry Buffer (pH) H2NNH2 Temp. (ºC) Time (h) Additive Cleavage 
1 Tris (7.5) – 23 15 – – 
2 Tris (7.5) – 37 15 – – 
3 Tris (7.5) + 23 15 – + 
4 Tris (7.5) + 37 1 – + 
5 Tris (7.5) + 37 15 – + 
6 Tris (7.5) NH2OH 37 15 – – 
7 Tris (7.5) – 23 15 0.4% SDS – 
8 Tris (7.5) – 100 5 min. 4×SB – 
9 HEPES (5.8) – 23 15 – – 
10 PBS (7.4) – 23 15 – – 
11 MI (3.0) – 23 15 – – 
12 MI (4.0) – 23 15 – – 
13 MI (5.0) – 23 15 – – 
14 MI (6.0) – 23 15 – – 
[a] Concentrations used: [Substrate] = 10 mM; [H2NNH2] = [NH2OH] = 100 mM; [Tris] = 100 mM; [HEPES] = 
50 mM. PBS (phosphate buffered saline): 10 mM Na2HPO4, 1.8 mM KH2PO4, 0.14 M NaCl, 2.7 mM KCl. MI 
(McIlvaine’s buffers): combinations of 0.1 M citric acid and 0.2 M Na2HPO4. SB (sample buffer): 20 mM Tris, 




Figure S1: LC-MS spectra of samples from entry 2 and 5 (Table S1), gradient: 10% → 90% ACN/0.1% aq. 
TFA. 
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 Optimization of the cleavage: hydrazine concentration & temperature 
 
Lane 1 2 3 4 5 6 7 8 9 10
Probe (2.5 µM)
PS
1 1 1 1 1 1 1 1 21
[H2NNH2] (mM) 100 0 1 10 50 100 100 0 0
T (ºC) 23 23 23 23 23 23 23 37 37










Lane 1 2 3 4 5 6 7 8 9
Probe (2.5 µM) 1 1 1 1 1 1 1 1 21
[H2NNH2] (mM) 100 0 1 10 50 100 100 100 100
T (ºC) 37 37 37 37 37 37 37 23 37




Figure S2: Search for the optimal cleavage conditions in a biological environment. HEK-293T cell lysate was 
incubated with probe 1 or 21 (2.5 µM final concentration) for 1 h at 37 ºC followed by denaturation (except for 
lanes 7 and 8 of the lower gel). Samples were treated with the indicated hydrazine concentration for 15 h, 
resolved by SDS-PAGE and all biotinylated proteins were visualized by anti-biotin Western blotting. Cleavage 
of the linker is shown by disappearance of the bands. PS: prestained marker low range (Bio-Rad). [a] Samples 
were pre-boiled with 1% SDS prior to incubation as a negative control. [b] 20 mM SDS without denaturing. [c] 
pH 8.5 is the pH value for a combination of 100 mM Tris and 100 mM hydrazine and was reached by addition of 
1 µL 1 M Tris to the sample. 
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Optimization of the cleavage: time dependence 
 
1 2 3 4 5 6 7 8 9







Figure S3: Time dependence of the hydrazine mediated cleavage in a biological environment. HEK-293T cell 
lysate was incubated with 2.5 µM (final concentration) probe 1 (Lanes 2-8) or 21 (lane 1) for 1 h at 37 ºC 
followed by denaturation. Samples were treated with hydrazine (100 mM) for 0.5, 1, 3, 5, 16 or 24 hours, 
resolved by SDS-PAGE and all biotinylated proteins were visualized by anti-biotin Western blotting. Cleavage 
of the linker is shown by disappearance of the bands. BM: biotinylated marker low range (Bio-Rad). Lane 2: no 





HEK-293 cell lysate (containing some 1.3 mg of protein) was incubated with 20 μM ABPs 1 or 21 for 1 h at 37 
°C, denatured by boiling for 5 min with 1% SDS and precipitated with chloroform/methanol (C/M).[6] The 
protein pellet was rehydrated in 180 μL 8 M urea/100 mM NH4HCO3, reduced with 10 μL 90 mM DTT for 30 
min at 37 °C, alkylated with 15 μL 200 mM iodoacetamide at RT in the dark, cleared by centrifugation at 13,000 
g and desalted by C/M. The pellet was dispersed in 25 μL pull down (PD) buffer (50 mM Tris·HCl pH 7.5, 150 
mM NaCl) with 2% SDS in a heated (37 °C) sonic bath. Stepwise (3  25 μL, 4  100 μL, 1  500 μL) addition 
of PD buffer afforded a clear solution that was incubated with 50 μL MyOne T1 Streptavidin grafted magnetic 
beads (Invitrogen) at RT with vigorous shaking for 1 h. The beads were stringently washed with 2  300μL PD 
buffer with 0.1% SDS, 2  300 μL PD buffer, 2  300 μL wash buffer I (4 M urea/50 mM NH4HCO3), 2  300 
μL wash buffer II (50 mM Tris·HCl pH 7.5, 10 mM NaCl) and 2  300 μL water. All 5 samples from ABP 1 
were mixed and divided over 8 equal portions. The same was done for the 2 samples from ABP 21, which were 
divided over 3 equal portions. To the samples was added 65 µL of the appropriate cleavage cocktail (see Figure 
2 in the article) and the samples were shaken for 15 h at RT or at 37 ºC. Next, the supernatant was removed, 
diluted with 20 µL 4 sample buffer and boiled at 100 ºC for 5 min. One sample from ABP 21 was treated 
directly with 85 µL 1 sample buffer containing 10 µM biotin, boiled at 100 ºC for 5 min and stored o/n at 4 ºC. 
The samples were resolved by 12.5% SDS-PAGE (25 µL of each sample was loaded) and all proteins were 
visualized by silverstain. The appropriate bands were cut from the gel and an in-gel digestion was performed 
according to the procedure described in literature.[7] 
After removal of the supernatant all beads were stringently washed as described above, eluted with 85 µL 1 
sample buffer containing 10 µM biotin at 100 ºC for 5 min., resolved on SDS-PAGE and visualized by 
silverstain to determine the cleavage efficiency (see Figure S4). 
 
LC-MS/MS analysis 
Trytic peptides were analyzed on a Surveyor nanoLC system (Thermo) hyphenated to a LTQ-Orbitrap mass 
spectrometer (Thermo). Gold and carbon coated emitters (OD/ID = 360/25 μm tip ID = 5 μm), trap column 
(OD/ID = 360/100 μm packed with 25 mm robust Poros®10R2/15 mm BioSphere C18 5 μm 120 Å) and 
analytical columns (OD/ID = 360/75 μm packed with 20 cm BioSphere C18 5 μm 120 Å) were from 
Nanoseparations (Nieuwkoop, The Netherlands). The mobile phases (A: 0.1% FA/H2O, B: 0.1% FA/ACN) were 
made with ULC/MS grade solvents (Biosolve). The emitter tip was coupled end-to-end with the analytical 
column via a 15 mm long TFE teflon tubing sleeve (OD/ID 0.3  1.58 mm, Supelco, USA) and installed in a 
stainless steel holder mounted in a nanosource base (Upchurch scientific, Idex, USA). General mass 
spectrometric conditions were: an electrospray voltage of 1.8 kV was applied to the emitter, no sheath and 
auxiliary gas flow, ion transfer tube temperature 150 ºC, capillary voltage 41 V, tube lens voltage 150 V. Internal 
mass calibration was performed with air-borne protonated polydimethylcyclosiloxane (m/z = 445.12002) and the 
plasticizer protonated dioctyl phthalate ions (m/z = 391.28429) as lock mass.[8] For shotgun proteomics analysis, 
10 μL of the samples was pressure loaded on the trap column with a 10 μL/min flow for 5 min. followed by 
peptide separation with a gradient of 35 min. 5 → 30% B, 15 min. 30 → 60% B, 5 min. A at a flow of 300 
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μL/min split to 250 nL/min by the LTQ divert valve. For each data dependent cycle, one full MS scan (300-2000 
m/z) acquired at high mass resolution (60,000 at 400 m/z, AGC target 1  106, maximum injection time 1,000 
ms) in the Orbitrap was followed by 3 MS/MS fragmentations in the LTQ linear ion trap (AGC target 5  103, 
max injection time 120 ms) from the three most abundant ions.[9] MS/MS settings were: collision gas pressure 
1.3 mT, normalized collision energy 35%, ion selection threshold of 500 counts, activation q = 0.25 and 
activation time of 30 ms. Fragmented precursor ions that were measured twice within 10 s were dynamically 
excluded for 60 s and ions with z < 2 or unassigned were not analyzed. Data from MS/MS was validated 
manually. The results are shown in Table S2 and in the LC-MS/MS spectra for the active site fragments of the 
2 and 5 subunits. 
  
 
Figure S4: Determination of the cleavage efficiency. The beads from the samples in Figure 2 after hydrazine 
mediated cleavage were washed extensively and boiled for 5 min. with sample buffer (20 mM Tris, 1% SDS, 
10% glycerol, 0.05% BPB, -mercaptoethanol) containing 10 µM biotin. Samples were resolved by SDS-PAGE 
and all proteins were visualized by silverstain. [a] The numbers correspond to the same samples in the lanes in 




Table S2: Identified proteasome -subunit peptides after pull-down and tryptic digest.[a] 









IPI00000811 (β1) 21890 39.0% 2 0.90 25.8 FAVATLPPA # 
    2 0.37 49.0 QVLLGDQIPK 
    2 0.90 40.7 QVLLGDQIPK 
    2 6.21 43.9 QVLLGDQIPK 
    2 0.81 85.0 LAAIAESGVER 
    2 0.10 98.6 EECLQFTANALALAMER 
    2 0.50 96.3 EECLQFTANALALAMER 
    3 0.00 71.1 YREDLMAGIIIAGWDPQEGGQVYSVPMGGMMVR * 
        
IPI00003217 (β2) 25279 42.7% 2 0.69 78.1 DGIVLGADTR 
    3 0.51 51.0 FRPDMEEEEAK 
    2 0.14 51.9 LDFLRPYTVPNK 
    2 1.01 144.9 LPYVTMGSGSLAAMAVFEDK 
    2 2.00 104.9 LPYVTMGSGSLAAMAVFEDK 
    3 2.47 62.4 LPYVTMGSGSLAAMAVFEDK 
    2 0.00 118.4 LPYVTMGSGSLAAMAVFEDK 
    2 1.12 99.6 ITPLEIEVLEETVQTMDTS # 
    2 2.31 102.1 ITPLEIEVLEETVQTMDTS # 
    2 0.42 119.1 NLVSEAIAAGIFNDLGSGSNIDLCVISK 
        
IPI00479306 (β5) 22444 54.4% 2 1.45 75.2 LLANMVYQYK 
    2 0.72 73.3 LLANMVYQYK 
    2 0.08 94.0 ATAGAYIASQTVK 
    2 1.33 79.7 GPGLYYVDSEGNR 
    2 0.20 97.7 DAYSGGAVNLYHVR 
    2 0.48 96.1 GYSYDLEVEQAYDLAR 
    2 0.71 71.8 ISGATFSVGSGSVYAYGVMDR 
    2 1.73 115.6 ISGATFSVGSGSVYAYGVMDR 
    3 1.39 61.0 VIEINPYLLGTMAGGAADCSFWER 
[a] Protein name, mass of the active β subunit, % coverage of the protein by amino acids identified by LC-MS, 
charge of the peptide (z), measurement error (ppm), Mascot peptide scores, miss cleavage (*), and C-terminal 
peptides (#). Mascot identifications were manually validated. 
 
Table S3: Calculated exact (m/z) masses of the active-site peptides bound to compound 1 after cleavage.[a] 
  Exact mass z=1 z=2 z=3 
  mono-iso High-peak mono-iso High-peak mono-iso High-peak mono-iso High-peak 
1 C123H203N27O36S 2666.4605 2667.4638 2667.4678 2668.4711 1334.2375 1334.7392 889.8274 667.8732 
2 C84H140N14O21 1681.0317  1682.0390  841.5232 842.0248 561.3512  
5 C76H126N12O19 1510.9262  1511.9335  756.4704  504.6493  
[a] The mono-isotopic (mono-iso) and the mass of the most abundant (High-peak) are shown at charge (z) of 1, 2 
and 3. The missing high peaks are absent because the mono-isotopic peak is also the highest peak. 
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LC-MS of the enriched 2 subunit active site 
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Labeling of proteasome active subunits with compound 19 followed by Staudinger-
















Figure S5: HEK-293 cell lysate (some 13.5 µg) was incubated with indicated final concentrations of compound 
19 or AdaKBio (21) for 1 h at 37 ºC followed by Staudinger-Bertozzi ligation (400 µM final concentration 
biotin-phosphane 25,[10] 2 h at 37 ºC) and SDS-PAGE. Read-out by streptavidin Western blotting. PS = 
prestained marker low range (Bio-Rad). [a] Negative control: sample was denatured (5 min. at 100 ºC with 1% 
SDS) prior to incubation with 19 (1 µM) and Staudinger-Bertozzi ligation. 
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Stability of the cleavable linker in blood serum and plasma 
Plasma and serum were collected from blood voluntarily donated by a healthy person. For plasma collection: 
blood was extracted in an EDTA tube and centrifuged for 15 min. at 4,000 g. For serum collection no EDTA was 
used. All experiments were executed in duplo. A volume of 100 L plasma or serum was incubated with 
compound 1 (10 M final concentration) with or without hydrazine (100 mM final concentration) for 15 h at 37 
°C. Next, 900 L of cooled (–20 °C) acetone was added and the samples were kept at –20 °C for 2 h and an 
additional 1 h at –80 °C. This was followed by centrifuging of the samples for 10 min. at 14,000 g, after which 
all acetone was evaporated under reduced pressure. The resulting yellowish pellet was extracted with 100 L 
ACN/H2O/tBuOH (1:1:1) for 5 min. and the samples were analyzed by LC-MS (injection of 20 L of the extract, 
system B, 10% → 90% ACN/0.1% aq. TFA). The LC-MS spectra are shown below. No products resulting from 
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